Hypernatriemia as a risk factor for cardio-renal syndrome in chronic heart failure


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Hyponatriemia is frequent in chronic heart failure (CHF) patients and always is associated with unfavorable prognosis. Pathophysiology of hyponatriemia in CHF and approaches to it’s therapeutic correction are discussed.

Full Text

Restricted Access

References

  1. Schrier R.W. Body water homeostasis: clinical disorders of urinary dilution and concentration // J. Am. Soc. Nephrol. — 2006; 17, 1820—1832.
  2. Hawkins R.C. Age and gender as risk factors for hyponatremia and hypernatremia // Clin. Chim. Acta. — 2003; 337, 169—172.
  3. Schrier R.W., Sharma S., Shchekochikhin D. Hyponatraemia: more than just a marker of disease severity? // Nat Rev Nephrol. — 2013;9(1):37—50.
  4. Ayus J.C., Achinger S.G., Arieff A. Brain cell volume regulation in hyponatremia: role of sex, age, vasopressin, and hypoxia // Am. J. Physiol. Renal Physiol. — 2008; 295, F619-F624.
  5. Gankam Kengne F., Andres C. et al. Mild hyponatremia and risk of fracture in the ambulatory elderly. // QJM. — 2008;101, 583-588.
  6. Verbalis J.G., Barsony J., Sugimura Y. et al. Hyponatremia-induced osteoporosis // J. Bone Miner. Res. - 2010; 25, 554-563.
  7. Shchekochikhin D.Y., Schrier R.W., Lindenfeld J. et al. Outcome Differences in Community-versus Hospital-Acquired Hyponatremia in Patients with a Diagnosis of Heart Failure // Circ Heart Fail. - 2013;6(3):379-386
  8. Gheorghiade M., Gattis W.A., O'Connor C.M. et al. Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators.Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial// JAMA. — 2004; 291:1963—1971.
  9. Gheorghiade M., Niazi I., Ouyang J. et al. Tolvaptan Investigators. Vasopressin V2-receptor blockade with Tolvaptan in patients with chronic heart failure: results from a double-blind randomized trial // Circulation. — 2003; 107:2690—2696.
  10. Konstam M., Gheorghiade M., Burnett J. et al. Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure: The EVEREST Outcome Trial // JAMA. — 2007; 297:1319 —1331.
  11. Gheorghiade M., Konstam M.A., Burnett J.C. Jr. et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials // JAMA. — 2007; 297:1332—1343.
  12. Adrogue' H.J., Madias N.E. Hyponatremia. // N Engl J Med. — 2000; 342:1581—1589.
  13. Shah M.R., O’Connor C.M., Sopko G. et al. Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE): design and rationale // Am Heart J. — 2001; 141:528—535
  14. Binanay C., Califf R.M., Hasselblad V. et al. ESCAPE Investigators and ESCAPE Study Coordinators. Evaluation Study of Congestive Heart Failure and Pulmonary ArteryCatheterization Effectiveness: the ESCAPE trial // JAMA. — 2005; 294:1625—1633.
  15. Schrier R.W., Abraham W.T. Hormones and hemodynamics in heart failure // N Engl J Med. — 1999; 341:577—585.
  16. Gheorghiade M., Abraham W.T., Albert N.M. et al. OPTIMIZE-HF Investigators and Coordinators.Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry // Eur Heart J. — 2007; 28:980—988.
  17. Gheorghiade M., Rossi J.S., Cotts W. et al. Characterization and Prognostic Value of Persistent Hyponatremia in Patients With Severe Heart Failure in the ESCAPE Trial // Arch Intern Med. — 2007; 167:1998—2005.
  18. Lee W.H., Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure // Circulation. — 1986; 73:257—267.
  19. Lee D.S., Austin P.C., Rouleau J.L. et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model // JAMA. — 2003; 290:2581—2587.
  20. Klein L., O'Connor C.M., Leimberger J.D. et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure (OPTIME-CHF) study // Circulation. — 2005; 111:2454—2460.
  21. Gottlieb S.S., Abraham W., Butler J. et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure // J. Card. Fail. — 2002; 8:136—141.
  22. Bettari L. et al. Hyponatremia and long-term outcomes in chronic heart failurean observational study from the Duke Databank for Cardiovascular Diseases // J. Card. Fail. — 2012; 18, 74—81.
  23. Allen L.A. et al. Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life. Circ. Cardiovasc. Qual. Outcomes. — 2011; 4, 389—398.
  24. Forfia P.R., Mathai S.C., Fisher M.R. et al. Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension // Am J Respir Crit Care Med. — 2008;177(12):1364—1369.
  25. Scherz N., Labarère J., Méan M. et al. Prognostic importance of hyponatremia in patients with acute pulmonary embolism // Am J Respir Crit Care Med. — 2010 ;182(9):1178—1183.
  26. Crestanello J.A., Phillips G., Firstenberg M.S. et al. Preoperative hyponatremia predicts outcomes after cardiac surgery // J Surg Res. — 2013;181(1):60—66.
  27. Szatalowicz V.L., Arnold P.E., Chaimovitz C. et al. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure // N. Engl. J. Med. — 1981; 305, 263—266.
  28. Riegger G.A., Leibau G., Kochsiek K. Antidiuretic hormone in congestive heart failure // Am. J. Med. — 1982; 72, 49.
  29. Goldsmith S.R., Francis G.S., Cowley A.W. et al. Increased plasma arginine vasopressin levels in patients with congestive heart failure // J. Am. Coll. Cardiol. — 1985; 1, 1385.
  30. Kim J.K., Michel J.B., Soubrier F. et al. Arginine vasopressin gene expression in chronic cardiac failure in rats // Kidney Int. — 1990; 38, 818—822.
  31. Schrier R.W., Berl T., Anderson R.J. Osmotic and nonosmotic control of vasopressin release // Am J Physiol. — 1979;236(4):F321—F332G.
  32. Gassanov N., Semmo N., Semmo M. et al. Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH) // Eur J Clin Pharmacol. — 2011;67:333—346.
  33. Schrier R.W. Body fluid regulation in health and disease: A unifying hypothesis // Ann Int Med. — 1990; 113:155—159.
  34. Shchekochikhin D., Tkachenko O., Schrier R.W. Hyponatremia: an update on current pharmacotherapy // Expert Opin Pharmacother. —2013; 14(6):747—755.
  35. Abraham W., Shamshirsaz A., McFann K. et al. Aquaretic effect of lixivaptan, an oral non-peptide selective V2 receptor vasopressin antagonist, in the New York Heart Association Functional class II and III chronic failure patients // J. Am. Coll. Cardiol — 2006;47:1615—1621.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies